Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.120
-0.020 (-1.75%)
May 7, 2025, 2:18 PM EDT - Market open
Femasys Employees
As of December 31, 2024, Femasys had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees increased by 37 or 108.82% compared to the previous year.
Employees
71
Change (1Y)
37
Growth (1Y)
108.82%
Revenue / Employee
$22,945
Profits / Employee
-$265,023
Market Cap
30.41M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
Eli Lilly and Company | 47,000 |
FEMY News
- 5 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations - GlobeNewsWire
- 7 weeks ago - Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewsWire
- 7 weeks ago - Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach - GlobeNewsWire
- 2 months ago - Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials - GlobeNewsWire
- 3 months ago - Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices - GlobeNewsWire
- 3 months ago - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control - GlobeNewsWire
- 3 months ago - Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - GlobeNewsWire